TransAlta (TAC) closed the last trading session at $8.99, gaining 22.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $13.26 indicates a 47.5% upside potential. The average comprises seven short-term price targets ranging from a low of $10.90 to a high of $19.18, with a standard deviation of $3.52. While the lowest estimate indicates an increase of 21.3% from the current price le ...

CALGARY, Alberta, Aug. 22, 2024 (GLOBE NEWSWIRE) -- TransAlta Corporation ("TransAlta" or the "Company") (TSX: TA; NYSE: TAC) announced today that it does not intend to exercise its right to redeem all or any part of the currently outstanding cumulative redeemable rate reset first preferred shares Series G ("Series G Shares") (TSX: TA.PR.J) on September 30, 2024 (the "Conversion Date"). As a result, the holders of the Series G Shares will have the right to convert all or any of their Series G Shares into cu ...

Generated record Q2 Contribution ex-TAC, programmatic revenue and CTV revenue Achieved 27% year-over-year Adjusted EBITDA growth in Q2 2024 while expanding Adjusted EBITDA Margin as a percentage of Contribution ex-TAC to 32% from 26% in Q2 2023 Reaffirming full year 2024 Contribution ex-TAC and Adjusted EBITDA guidance Launched $50 million Ordinary Share repurchase program and fully repaid the Company's outstanding longterm debt in Q2 2024 NEW YORK, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Nexxen International Ltd ...

stuckreed/iStock via Getty Images For 2024 Investment case TransAlta Corponation (TSX:TA.CA) (NYSE:TAC) continus: its strong performance. Since my last publication on May 1, TimasAlta: Prefereds, Offer Lucative Yields, Common Share TA:CA - TransAlta Corporation $11.42 -0.055 (-0.48%) 11.27 AM 08/20/24 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |---------------------------------------|-------|----------|-------|-------|------------------------|-----------|---------------- ...

TransAlta Corporation (TAC) is committed to being a leader in clean electricity by delivering customercentered power solutions. The company benefits from its focus on sustainable energy projects. Given its growth opportunities, TAC makes for a solid investment option in the utility sector. The company currently carries a Zacks Rank #2 (Buy). Let's look at the factors that are driving the stock. Growth Projections & Surprise History The Zacks Consensus Estimate for 2024 earnings per share (EPS) has increased ...

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies. Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors rely on traditional forms of ...

TransAlta Corporation (TAC) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, TAC's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross." A golden cross is a technical chart pattern that can signify a potential bullish breakout. It's formed from a crossover involving a security's short-term moving average breaking above a longer-term moving average, with the most common moving averages ...

TransAlta (TAC) closed the last trading session at $8.05, gaining 9.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $13.12 indicates a 63% upside potential. The average comprises seven short-term price targets ranging from a low of $10.08 to a high of $19.18, with a standard deviation of $3.64. While the lowest estimate indicates an increase of 25.2% from the current price level ...

Core Insights - Taboola reported strong financial performance for Q2 2024, with revenues of $428.2 million, a 29% year-over-year increase, and a significant reduction in net loss to $4.3 million from $31.3 million in Q2 2023 [1][3][4] - The company is focusing on growth through partnerships and AI investments, with expectations for continued revenue and profit growth in Q3 and FY 2024 [4][6] Financial Performance - Q2 2024 financial highlights include: - Revenues: $428.2 million, up from $332.0 million in Q2 2023 - Gross profit: $114.8 million, compared to $97.1 million in the previous year - Net loss: $4.3 million, significantly improved from $31.3 million [1][5] - Year-over-year growth rates for key metrics: - Revenues: +29% - ex-TAC Gross Profit: +21% - Adjusted EBITDA: +138% - Free Cash Flow: +237% [1][6] Guidance and Projections - Q3 2024 guidance includes: - Revenues: $431 million (+20% YoY) - Gross profit: $134 million (+33% YoY) - Adj. EBITDA: $47 million (+106% YoY) [1][7] - Full Year 2024 guidance: - Revenues: $1.735-$1.765 billion - ex-TAC Gross Profit: $667 million (+25% YoY) - Adj. EBITDA: $200 million+ (2x+ YoY) [1][7] Strategic Initiatives - The company completed the migration of Yahoo advertisers and is ramping up spending, indicating a focus on user engagement and revenue generation [2][6] - Taboola launched "Audience Solution" to assist publishers in traffic growth, and secured a significant exclusive global OEM partnership with Taboola News [2][6] Market Position and Future Outlook - CEO Adam Singolda emphasized the transformational nature of 2024 for Taboola, driven by AI investments and partnerships with major brands like Yahoo and Apple [4][6] - The company aims to capture a share of the growing digital advertising market, projected to reach a trillion dollars [4][6]

Patient enrollment has accelerated, now with 13 patients enrolled in trial TFF TAC at ~20% of the oral tacrolimus dose prevented acute rejection and achieved >80% of the previous oral trough blood levels -- leading to diminished drug burden 9 out of 9 (100%) patients who completed the 12-week treatment chose to remain on TFF TAC by proceeding to the long-term extension Phase; 2 patients have been treated for over a year and 6 patients have been treated for more than 6 months Observed a 6.5-fold reduction in ...